PBX-7016

Tra-LP1 (3-10 mg/kg; intravenous injection; once weekly for 2 consecutive weeks), an ADC conjugated with PBX-7016, exhibits dose-dependent antitumor activity in BALB/c nude mice bearing JIMT-1 breast cancer xenografts. Under the regimen of intravenous injection once weekly for 2 consecutive weeks, the TGI reaches 65.5% in the 3 mg/kg dose group and 79.5% in the 10 mg/kg dose group, with no systemic toxicity observed^[2].
The ADC Tra-LP1 (administered intravenously at 3-10 mg/kg) conjugated with PBX-7016 exhibits dose-dependent antitumor activity in nude mice bearing NCI-N87 gastric cancer xenografts, with a TGI of 43.0% at 3 mg/kg and 114.4% at 10 mg/kg, and no significant body weight loss is observed^[2].
Nim-LP1 (5 mg/kg; intravenous injection; once weekly for 2 weeks), an EGFR-targeting ADC conjugated with PBX-7016, exhibits potent, target-specific anti-tumor activity in nude mice bearing EGFR-positive MDA-MB-468 breast cancer xenografts, with a TGI of 115.8%, and no significant body weight loss is observed^[2].